Describes a highly sensitive HPLC method for measuring Adriamycin and its metabolites in biological fluids.
Does not support clinical adoption; extends lab methods for Adriamycin research.
A definitive approach to the analysis of plasma, bile, and urine levels of the widely used antitumor drug Adriamycin using two complementary high performance liquid chromatographic systems, one normal phase and the other reversed phase, is described. Sensitivity in the 2–10 picomole per sample range is achieved by means of fluorescence detection. The use of the two systems in parallel provides an unequivocal basis for the characterization and determination of Adriamycin and its principal metabolite, adriamycinol, and enables the measurement of anthracycline fluorescent aglycones and conjugates, as well.
No takes yet. Share an insight, caveat, or question.
Israel et al. (1978) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: